CELEBRATION, Fla. — March 5, 2026 — Leads & Copy — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has appointed Justin Renz as Chief Financial Officer, effective March 9, 2026. Renz brings over 25 years of financial leadership experience in the biopharmaceutical industry.
According to Zevra President and Chief Executive Officer Neil F. McFarlane, Renz has a strong track record of driving growth and creating shareholder value across multiple biopharmaceutical organizations. McFarlane said Renz’s financial leadership and experience driving performance across global markets will be instrumental as the company executes its strategic plan to become a leading rare disease company.
Renz most recently served as Chief Financial & Operations Officer at Ardelyx, where he played an active role in the launch and commercialization of two medicines. He previously served as President and Chief Financial Officer of Correvio Pharma, a global specialty pharmaceutical company. He also held the position of Executive Vice President, Chief Financial Officer and Treasurer at Karyopharm Pharmaceuticals, and Executive Vice President and Chief Financial Officer at Zalicus Inc.
Renz said he is excited to join Zevra at this important stage of growth and looks forward to working with the team to strengthen the company’s financial foundation and enable continued innovation and access to therapies.
Renz holds a B.A. in Economics and Accounting from the College of the Holy Cross, an M.S. in Taxation from Northeastern University, and an M.B.A. from Suffolk University. He is a Certified Public Accountant in Massachusetts.
Zevra Therapeutics, Inc. is focused on bringing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), provides a corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is guided by its values of accountability, integrity, innovation and courage.
Source: Zevra Therapeutics, Inc.
